Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 10, 2023
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
[ Wed, May 10th 2023
] - WOPRAI
Robert Burns Maintained (VIRX) at Strong Buy with Decreased Target to $33 on, May 10th, 2023
Robert Burns of HC Wainwright & Co., Maintained "Viracta Therapeutics, Inc." (VIRX) at Strong Buy with Decreased Target from $35 to $33 on, May 10th, 2023.
Robert has made no other calls on VIRX in the last 4 months.
There are 3 other peers that have a rating on VIRX. Out of the 3 peers that are also analyzing VIRX, 0 agree with Robert's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Robert
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $7 on, Tuesday, May 9th, 2023
- Andrew Berens of "SVB Securities" Maintained at Buy and Held Target at $11 on, Monday, May 8th, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $16 on, Monday, March 27th, 2023
